The global expansion of GLP-1 therapies — such as Ozempic, Wegovy, and Mounjaro — is vastly misunderstood. This is not a pharmaceutical headline about weight loss or a clinical story — it is a $200 billion structural reallocation of global consumer capital. As biological hunger is systematically moderated across affluent markets, household expenditure is undergoing a permanent portfolio reset. Capital is fleeing volume-driven indulgence — processed foods, mass dining, and bulk alcohol — and compounding into a high-margin “longevity stack” centered on muscle preservation, real-time health intelligence, regenerative aesthetics, and vitality-focused luxury travel.